Nature Communications (Mar 2021)
Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma
- Daniel Schäfer,
- Stefan Tomiuk,
- Laura N. Küster,
- Wa’el Al Rawashdeh,
- Janina Henze,
- German Tischler-Höhle,
- David J. Agorku,
- Janina Brauner,
- Cathrin Linnartz,
- Dominik Lock,
- Andrew Kaiser,
- Christoph Herbel,
- Dominik Eckardt,
- Melina Lamorte,
- Dorothee Lenhard,
- Julia Schüler,
- Philipp Ströbel,
- Jeannine Missbach-Guentner,
- Diana Pinkert-Leetsch,
- Frauke Alves,
- Andreas Bosio,
- Olaf Hardt
Affiliations
- Daniel Schäfer
- Miltenyi Biotec GmbH, R&D
- Stefan Tomiuk
- Miltenyi Biotec GmbH, R&D
- Laura N. Küster
- Miltenyi Biotec GmbH, R&D
- Wa’el Al Rawashdeh
- Miltenyi Biotec GmbH, R&D
- Janina Henze
- Miltenyi Biotec GmbH, R&D
- German Tischler-Höhle
- Miltenyi Biotec GmbH, R&D
- David J. Agorku
- Miltenyi Biotec GmbH, R&D
- Janina Brauner
- Miltenyi Biotec GmbH, R&D
- Cathrin Linnartz
- Miltenyi Biotec GmbH, R&D
- Dominik Lock
- Miltenyi Biotec GmbH, R&D
- Andrew Kaiser
- Miltenyi Biotec GmbH, R&D
- Christoph Herbel
- Miltenyi Biotec GmbH, R&D
- Dominik Eckardt
- Miltenyi Biotec GmbH, R&D
- Melina Lamorte
- Charles River Discovery Research Services GmbH
- Dorothee Lenhard
- Charles River Discovery Research Services GmbH
- Julia Schüler
- Charles River Discovery Research Services GmbH
- Philipp Ströbel
- University Medical Center Göttingen, Institute for Pathology
- Jeannine Missbach-Guentner
- University Medical Center Göttingen, Institute for Diagnostic and Interventional Radiology
- Diana Pinkert-Leetsch
- University Medical Center Göttingen, Institute for Diagnostic and Interventional Radiology
- Frauke Alves
- University Medical Center Göttingen, Clinic for Hematology and Medical Oncology
- Andreas Bosio
- Miltenyi Biotec GmbH, R&D
- Olaf Hardt
- Miltenyi Biotec GmbH, R&D
- DOI
- https://doi.org/10.1038/s41467-021-21774-4
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 18
Abstract
There is an unmet clinical need to identify therapeutic options for the treatment of pancreatic cancer (PDAC). Here the authors present a systematic screening approach for the identification of potential PDAC cell surface target candidates for CAR-T cell based immunotherapy, followed by their functional validation in preclinical models.